Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 40464  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »Related articles
  »  Article in PDF (683 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Subjects and Methods
 » Results
 » Discussion
 »  References
 »  Article Tables

 Article Access Statistics
    Viewed398    
    Printed16    
    Emailed0    
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2021  |  Volume : 69  |  Issue : 6  |  Page : 1655-1662

Cryptogenic Stroke in the Young: Role of Candidate Gene Polymorphisms in Indian Patients with Ischemic Etiology


1 Department of Neurological Sciences, Christian Medical College – Vellore, Vellore, Tamil Nadu, India
2 Department of General Medicine, Christian Medical College – Vellore, Vellore, Tamil Nadu, India

Date of Web Publication23-Dec-2021

Correspondence Address:
Dr. Christhunesa S Christudass
Department of Neurological Sciences, Neurochemistry Division, Christian Medical College, Vellore - 632 004, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.333441

Rights and Permissions

 » Abstract 


Context: Strokes that remain without a definite cause even after an extensive workup, termed cryptogenic strokes, constitute up to 30–40% of ischemic strokes (ISs) in the young. Some of them can have a genetic basis. However, the well-established genetic causes account for only a small percentage of these cases.
Aim: To evaluate the association of cryptogenic young IS with 16 candidate gene polymorphisms.
Settings and Design: A case-control study with cryptogenic young IS patients (South and North Indians; n = 105) and age, sex, and ethnicity-matched controls (n = 215).
Subjects and Methods: Genotyping was carried out by PCR-RFLP method using DNA extracted from the blood.
Statistical Analysis Used: Association of the genotypes with the disease was studied using Chi-square test.
Results: MTHFR rs1801133 and KNG1 rs710446 showed significant statistical association with cryptogenic young IS (P = 0.0261 and 0.0157, respectively) in the Indian population. Significant association of KNG1 rs710446 (P 0.0036) and FXII rs1801020 (P 0.0376) with cryptogenic young stroke in South Indian males, SERPINC1 rs2227589 in South Indian female patients (P = 0.0374), and CYP4V2 rs13146272 in North Indian males (P = 0.0293) was observed.
Conclusions: Our study indicates that in the Indian population MTHFR rs1801133, KNG rs710446, FXII rs1801020, SERPINC1 rs2227589, CYP4V2 rs13146272, and FXIII V34L may be significant risk factors for cryptogenic IS in the young. In addition, ethnicity and gender play a significant role. Further studies with larger sample size are required to completely establish these polymorphisms as risk factors for cryptogenic IS in young Indians.


Keywords: Cryptogenic young ischemic stroke, PCR-RFLP, single nucleotide polymorphisms
Key Message: In cryptogenic young ischemic stroke among Indian population, MTHFR rs1801133, KNG rs710446, FXII rs1801020, SERPINC1 rs2227589, CYP4V2 rs13146272, and FXIII V34L polymorphisms contribute a significant, ethnicity- and gender-specific risk.


How to cite this article:
Salomi BS, Solomon R, Turaka VP, Aaron S, Christudass CS. Cryptogenic Stroke in the Young: Role of Candidate Gene Polymorphisms in Indian Patients with Ischemic Etiology. Neurol India 2021;69:1655-62

How to cite this URL:
Salomi BS, Solomon R, Turaka VP, Aaron S, Christudass CS. Cryptogenic Stroke in the Young: Role of Candidate Gene Polymorphisms in Indian Patients with Ischemic Etiology. Neurol India [serial online] 2021 [cited 2022 Jan 18];69:1655-62. Available from: https://www.neurologyindia.com/text.asp?2021/69/6/1655/333441




Stroke, both ischemic and hemorrhagic, is a major cause of death and disability in the industrialized countries. Although young adults are at a lower risk of stroke compared to older people, its incidence ranges from 60 to 200 new cases per year per million inhabitants.[1],[2] Most of the strokes in the young age are of ischemic etiology[2],[3] and they are important in Indian context too.[4]

Compared with older adults, young patients (18-45 years) with ischemic stroke (IS) have a lower prevalence of the classical risk factors for atherosclerosis such as dyslipidemia, hypertension, diabetes mellitus, atrial fibrillation, and are also less likely to have an associated coronary or peripheral artery disease.[3],[5],[6],[7] This may suggest an underlying etiology only targeting the cerebrovascular system. Cryptogenic strokes are strokes that remain without a definite cause even after extensive workup and normally 30–40% of ISs in the young are cryptogenic.[8],[9],[10]

Data suggests that some of these cryptogenic strokes in the young can have a genetic basis and environmental factors can make them more susceptible. 32% of stroke deaths and 17% of stroke hospitalizations or stroke deaths in twins have been attributed to heritability.[11],[12] Having a positive family history of stroke was associated with a ≈30–76% increase in stroke risk.[12] It is also reported that younger stroke cases are more likely to have a positive family history of stroke than older cases or that age at stroke was inversely related to a family history of stroke.[13],[14],[15],[16],[17]

There are some well-established genetic causes for strokes. Among the more well-known disorders are Fabry disease, cerebral autosomal dominant [or recessive] arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL [or CARASIL]), mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), sickle-cell disease, homocystinuria, and Marfan syndrome.[18],[19],[20],[21] Even collectively, these disorders are rare and account for only a small percentage of young stroke cases.

The molecular basis for the genetic risk of IS is likely to be multigenic and influenced by environmental factors. It is possible that there may be other high-penetrance mutations segregating in some families also contribute to the burden of early-onset stroke. Candidate genes and pathways for IS generally fall into one of the following categories: (a) genes involved in coagulation and fibrinolytic system or genes encoding platelet glycoproteins,[18],[22],[23],[24] (b) genes in homocysteine metabolism,[23],[24],[25],[26] (c) genes involved with lipid metabolism,[18],[22] and (d) inflammation genes.[27] As with many candidate gene studies, the associations of these genes with stroke have generally been inconclusive because of insufficient sample size, heterogeneity in the study design, diversity of study populations, inconsistent phenotype classifications, and diverse inclusion/exclusion criteria for each study. Furthermore, relatively few of these studies have focused on younger populations, a group in which rare high-penetrance variants could theoretically account for disproportionately more of the disease burden.

This controversial situation led us to evaluate the association between cryptogenic young IS with some candidate gene polymorphisms along with the established Factor V Leiden, MTHFR C677T, and Prothrombin G20210A mutations. [Table 1] shows the SNPs screened for and the probable outcomes of these SNPs which could contribute to the manifestation of stroke.
Table 1: Details of the polymorphisms with primers and restriction enzymes used in identifying the polymorphisms

Click here to view



 » Subjects and Methods Top


Subjects

A case-control study with young (age 15 to 45 years) IS patients, comprising of both South and North Indians, and age-, sex-, and ethnicity-matched control subjects was carried out. Patients were consecutively recruited during their acute hospitalization or when attending as outpatients for follow up treatment in the Department of Neurological Sciences. Control subjects were healthy blood donors without any risk factors for stroke, randomly selected from the respective populations, matched for age and ethnicity. The study was approved by the Institutional review board.

An extensive workup of all the cases, apart from a detailed history and clinical examination, was carried to rule out an etiology. MRI with MRA was done to establish the diagnosis of the IS and to look for any radiological clues toward an etiology. In patients suspected to have vasculitis (primary or secondary vasculitis of the CNS), additional digital subtraction angiogram (DSA) was done. CSF analysis was carried out in cases when a CNS infection was suspected as the cause of the stroke. In patients suspected to have embolic stroke of undetermined source (ESUS), a complete work up ruled out any source for emboli.[44] Transthoracic ECHO was done in all patients and in suspected cases of paradoxical emboli, a Transcranial Doppler Bubble study was carried out. HOLTER was done in patients suspected to have an underlying cardiac arrhythmia.

Apart from the routine blood tests which included lipid profile; all patients were screened for antinuclear antibody (ANA), C & P antineutrophil cytoplasmic antibodies (ANCA) and C-reactive protein (CRP), and in suspected cases of Sjogren's syndrome screening of anti-SSA and SSB, and salivary gland biopsy was also carried out. All the patients had tested negative for HIV infection. A complete thrombotic workup was done which included assays of: Protein C (functional estimation was done using a chromogenic assay and if low, antigenic assay was done using ELISA), activated protein C resistance (APCR—estimated by clot-based method), Protein S (bound & Free—by ELISA), antithrombin III (using chromogenic assay), Factor VIII level (APTT-based single staged factor assay), Lupus anticoagulant (Dilute Russell Viper Venom Test), and anticardiolipin antibodies. Other tests such as serum homocysteine levels, paroxysmal nocturnal hemoglobinuria (Ham's and sucrose lysis test), and Sickle cell preparation were also carried out. Markers for thrombosis, which could be influenced by the acute thrombotic event (protein assays), were repeated after six months if they were found to be abnormal, to avoid a false positives result. For patients on oral anticoagulants, this was done after stopping oral anticoagulants for a minimum period of 6 weeks.

Genotype screening

Genomic DNA was isolated using QiaAmp Blood mini kit (Qiagen) from 2 ml peripheral blood sample collected in EDTA tubes from the participants. Genotyping was carried out by PCR-RFLP method. The primer sequences used for PCR and the restriction enzymes used for RFLP are given in [Table 1].

Statistical analysis

Statistical analysis was carried out using Vassar Stats. The prevalence of the variants was compared between patients and controls using Chi-square tests with Yates correction. Hardy–Weinberg equilibrium (HWE) for each genotype polymorphism was determined for control subjects with the Chi-square test. Univariate odds ratios (ORs) and 95% confidence intervals (CIs) were estimated whenever necessary. P values of <0.05 were considered to be statistically significant.


 » Results Top


A total of 105 young cryptogenic IS patients and 215 control subjects were recruited for this study. The mean age of the patients at the onset of stroke was 32.7 (± 7.7) years and the mean age of the controls was 31.8 (± 8.4) years. 77% of the cases (n = 79) were males. Among the study samples, 26 cases and 44 controls were from the North India. [Table 2] shows the prevalence of the various genotypes of the screened polymorphisms in the study population. All the polymorphisms were found to be well within the limits of Hardy–Weinberg equilibrium.
Table 2: Distribution of genotypes among cases and controls

Click here to view


MTHFR rs1801133 and KNG1 rs710446 showed significant statistical association with cryptogenic young IS (P = 0.0261 and 0.0157, respectively) in Indian population. The T allele of MTHFR rs1801133 was found to be statistically associated with cryptogenic young IS in Indian population (OR 1.8725; 95% CI: 1.1858–2.9570; P = 0.0071). While in KNG1 rs710446, the significance was found to be in having CC genotype (OR 3.0412; 95% CI: 1.3818–6.6934; P = 0.0057). We also found a trend of association (P = 0.0743) in Factor XII (FXII) rs1801020 polymorphism with cryptogenic young IS but the allelic frequency analysis showed a borderline protective effect (OR 0.7265; 95% CI: 0.5211-1.0128; P = 0.0595).

When the results were analysed based on their ethnicity, i.e., South and North Indians, KNG1 rs710446 showed significant association with cryptogenic young stroke only in South Indians (P = 0.0032) but not in North Indians [Table 2] and having CC genotype increased the risk around four times (OR 4.3885; 95% CI: 1.7576–10.9573; P = 0.0015). Though the genotype of FXII rs1801020 also showed an association (P = 0.0307) with cryptogenic young stroke in South Indians, the allelic frequencies revealed that the 'T' allele showed a protective effect in these patients (OR 0.6951; 95% CI: 0.4753–1.0166; P = 0.0608). Likewise, the CYP4V2 rs13146272 polymorphism was found to be associated to cryptogenic stroke significantly in North Indians (P = 0.03) and having AA genotype was found to increase the risk three times (OR 3.3333; 95% CI: 1.1508–9.6554; P = 0.0265). The FXIII V34L and MTHFR rs1801133 polymorphisms showed only a trend of association (P = 0.084 and 0.094, respectively) in South Indians, the allelic frequencies showed significant association and having T allele increased the risk of cryptogenic IS almost two times (OR 2.1372; 95% CI: 1.0286–4.4409; P = 0.0418 for FXIII V34L and OR 1.8079; 95% CI: 1.0513–3.1088; P = 0.0323 for MTHFR rs1801133).

When the results were analysed further based on their gender, we found a significant association of KNG1 rs710446 with cryptogenic young IS only in males (P = 0.0224) but it was more prominent in South Indian males (P = 0.0036) in which having C allele increased the risk approximately two fold (OR 1.9310; 95% CI: 1.1885–3.1373; P = 0.0079). Likewise, though FXII rs1801020 polymorphism was also found to be associated with stroke in males (P = 0.0305), the association was mainly because of South Indian males (P = 0.0376); however, the presence of the minor allele had a protective effect (OR 0.6043; 95% CI: 0.3763–0.9705; P = 0.0372). SERPINC1 rs2227589 showed a significant association in female cryptogenic young stroke patients (P = 0.0426), mainly because of the significant association in South Indian female patients (P = 0.0374) in whom having A allele increased the risk significantly (OR 2.7182; 95% CI: 1.2276–6.0185; P = 0.0137). On the other hand, CYP4V2 rs13146272 polymorphism was associated with stroke in North Indian males (P = 0.0293) and having A allele increased the risk of stroke almost two fold (OR = 1.963; 95% CI: 0.9732–3.9595; P = 0.0595) but the North Indian females could not be analyzed as very few of them were included in the study. MTHFR rs1801133 showed a trend of association only in males (P = 0.0699) and the T allele was found to be statistically associated with cryptogenic young IS in males (OR 1.9; 95% CI: 1.1063-3.266; P = 0.02). On the contrary, FXIII V34L showed a trend of association with the cryptogenic young IS in South Indians females (P = 0.061), with T allele showing significant association (OR 2.8134; 95% CI: 1.0579–7.4819; P = 0.0382). Except CYP4V2 rs13146272 polymorphism, we could not analyze the gender differences in other polymorphisms in North Indian population as the numbers were inadequate.


 » Discussion Top


Genetic predisposition resulting from polymorphisms in the coagulation factor genes is linked to an increased risk of thrombosis[45] and Factor V Leiden, Prothrombin G20210A mutation, and MTHFR C677T are some of the inherited polymorphisms reported to be involved in genetic risk of thrombosis.[46],[47] Neither Factor V Leiden mutation nor Prothrombin G20210A showed any association with cryptogenic young IS in our study population.

Several studies have shown an association between MTHFR rs1801133 polymorphism, hyperhomocysteinemia, and IS.[48],[49],[50],[51] In the present study, we have observed that the T allele of MTHFR rs1801133 polymorphism is associated with IS in males, more prominently in South Indian population but not in females. It is also worthy to note that 53% of those with this allele in our study had hyperhomocysteinemia. The contribution of this polymorphism in North Indian population can only be ascertained in a study with more number of samples as we faced limitations of recruiting young cryptogenic IS of North Indian origin.

The T>C substitution at the KNG1 T1742C polymorphic site which results in Ile581Thr substitution, has been reported to be associated with decreased aPTT values.[52] Shortening of activated partial thromboplastin time (aPTT) is associated with risk of thrombosis and IS.[52],[53],[54] Though this polymorphism showed significant statistical association with young IS, when we separately analyzed the data based on the two major ethnic groups (South and North Indian), the significance of this association was confined to South Indian male patients.

The risk allele A of rs2227589 (786 G>A), on intron 1 of SERPINC1 gene which codes for antithrombin has been reported to be associated with lower anticoagulant activity, decreased plasma anti-factor Xa, and decreased antithrombin levels.[36] Various studies have shown an association of IS with antithrombin deficiency.[55],[56] In our study also, a trend of association between the A allele of SERPINC1 rs2227589 and IS in young was noted. More careful analysis of the data has revealed a significant association of this polymorphism in only South Indian females. Its significance in North Indian patients could not be ascertained due to lack of enough cases and controls.

It has been reported that FXII plasma levels exhibit a 67% of heritability and that these levels are strongly determined by FXII gene variants.[57] Although low FXII plasma levels have been reported to affect the development of cerebrovascular diseases, it has been recently proposed that rather than the cause of thrombosis, these low levels might actually be the result of it.[58],[59] The FXII rs1801020 polymorphism which leads to 46C>T transition affects the translation efficiency, leading to reduced FXII plasma levels.[39] Previous genetic association studies between 46 C>T and cerebrovascular risk showed that genotype TT increases significantly the risk for venous thrombosis, IS, and acute coronary artery disease.[60],[61],[62] In our study, though FXII rs1801020 showed only a trend of association over all, it was found to be negatively associated with stroke in males especially in South Indian males i.e., the T allele showed a protective effect rather than a risk of stroke. Conversely, there are also studies that either do not detect genetic association between this genotype and thrombosis or alternatively report association between the CC genotype and cerebrovascular risk.[58],[63] Further studies in larger populations are needed to clarify the role this polymorphism.

FXIII Val134Leu, a common genetic single nucleotide polymorphism (SNP), is critically located near the thrombin activation site (R37-G38) of FXIII-A and has been demonstrated to affect the rate of FXIII activation peptide cleavage by thrombin, resulting in faster FXIII activation and more rapid fibrin clot formation[43] thus increasing the risk of thrombosis. In the present study, FXIII V34L showed a trend of association with the cryptogenic young IS in the South Indian females.

CYP4V2 rs13146272 is located close to the gene encoding coagulation factor XI and factor XI levels have been reported to be associated with IS.[64] This SNP is a missense variant (K259Q) of CYP4V2, and this SNP was most strongly associated with deep vein thrombosis (DVT) in many SNP association studies.[37],[65],[66] Ironically, the CYP4V2 gene encodes for a protein which is not known to be related to thrombosis, but its genetic effect on DVT susceptibility may be indirectly mediated through FXI protein with which level this marker is correlated.[37] The rs13146272 lies 67 kb upstream of the F11 gene, and this indirect effect may arise from a long-range transcriptional regulatory element of F11 encompassing the CYP4V2 SNP or its proxies.[67] Alternatively, the CYP4V2 SNP may be in high LD with another variant in or more proximal to the F11 gene that is capable of directly regulating F11 expression. We found that this polymorphism significantly increased the risk of stroke only in North Indian population, more evidently in men, but not in South Indian population.

To conclude, our study indicates that in the Indian population MTHFR rs1801133, KNG rs710446, FXII rs1801020, SERPINC1 rs2227589, CYP4V2 rs13146272, and FXIII V34L might be significant risk factors for cryptogenic IS in the young, and also ethnicity and gender play a significant role. However, the limitations of the study include the small population size, especially the North Indian population, and lack of sufficient study on the functional effects of these polymorphisms. Therefore, further validation of this study with the functional effects in a larger population size is required to completely establish these polymorphisms as risk factors for cryptogenic IS in the young Indian population.

Acknowledgments

The authors would like to thank the Christian Medical College and Hospital, Vellore, India, for funding this work under the fluid research grant scheme. We also acknowledge the help received from Dr. Joy J Mammen, Professor and Head, Department of Transfusion medicine and Immunohaematology, Christian Medical College, Vellore for the help in recruiting age-, sex-, and ethnicity-matched control subjects from among the blood donors.

Financial support and sponsorship

Fluid research grant (IRB Min. No. 9753 [Observe] dated 18-11-2015) from Christian Medical College and Hospital, Vellore, India.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Leys DD. Epidemiology of ischemic stroke in young adults. In: Pezzini A, Padovani A, editors. Cerebral Ischemia in Young Adults: Pathogenic and Clinical Perspectives. New York: Nova Science Publishers Inc.; 2009. p. 1-25.  Back to cited text no. 1
    
2.
Marini C, Carolei A. Epidemiology of stroke in the young. Stroke 2003;34:e13-4.  Back to cited text no. 2
    
3.
Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012;125:e2-220.  Back to cited text no. 3
    
4.
Prasad K, Singhal KK. Stroke in young: An Indian perspective. Neurol India 2010;58:343-50.  Back to cited text no. 4
[PUBMED]  [Full text]  
5.
Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: The Helsinki young stroke registry. Stroke 2009;40:1195-203.  Back to cited text no. 5
    
6.
Fromm A, Waje-Andreassen U, Thomassen L, Naess H. Comparison between ischemic stroke patients <50 years and ≥50 years admitted to a single centre: The Bergen stroke study. Stroke Res Treat 2011;2011:183256.  Back to cited text no. 6
    
7.
Nagaraja D, Gurumurthy SG, Taly AB, Subbakrishna K, Rao B, Sridhararama RB. Risk factors for stroke: Relative risk in young and elderly. Neurol India 1998;46:183-4.  Back to cited text no. 7
[PUBMED]    
8.
Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, et al. Infarcts of undetermined cause: The NINCDS stroke data bank. Ann Neurol 1989;25:382-90.  Back to cited text no. 8
    
9.
Lee BI, Nam HS, Heo JH, Kim DI; Yonsei Stroke Team. Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis 2001;12:145-51.  Back to cited text no. 9
    
10.
Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: A population-based study. Lancet Neurol 2015;14:903-13.  Back to cited text no. 10
    
11.
Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke: A long-term follow-up study of Danish twins. Stroke 2002;33:769-74.  Back to cited text no. 11
    
12.
Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004;35:212-27.  Back to cited text no. 12
    
13.
Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke 2004;35:819-24.  Back to cited text no. 13
    
14.
Lisabeth LD, Kardia SL, Smith MA, Fornage M, Morgenstern LB. Family history of stroke among Mexican-American and non-Hispanic white patients with stroke and TIA: Implications for the feasibility and design of stroke genetics research. Neuroepidemiology. 2005;24:96-102.  Back to cited text no. 14
    
15.
Lee YS, Chen DY, Chen YM, Chuang YW, Liao SC, Lin CS, et al. First-ever ischemic stroke in Taiwanese elderly patients: Predicting functional independence after a 6-month follow-up. Arch Gerontol Geriatr 2009;49(Suppl 2):S26-31.  Back to cited text no. 15
    
16.
Knottnerus IL, Gielen M, Lodder J, Rouhl RP, Staals J, Vlietinck R, et al. Estimating the magnitude of genetic factors by calculating the genetic relative risk of stroke in first-ever lacunar stroke patients. PLoS One 2011;6:e21439.  Back to cited text no. 16
    
17.
Yao XY, Lin Y, Geng JL, Sun YM, Chen Y, Shi GW, et al. Age- and gender-specific prevalence of risk factors in patients with first-ever ischemic stroke in china. Stroke Res Treat 2012;2012:136398.  Back to cited text no. 17
    
18.
Dichgans M. Genetics of ischaemic stroke. Lancet Neurol 2007;6:149-61.  Back to cited text no. 18
    
19.
Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010;41:78-81.  Back to cited text no. 19
    
20.
Ballabio E, Bersano A, Bresolin N, Candelise L. Monogenic vessel diseases related to ischemic stroke: A clinical approach. J Cereb Blood Flow Metab 2007;27:1649-62.  Back to cited text no. 20
    
21.
Devaraddi N, Jayalakshmi G, Mutalik NR. CARASIL, a rare genetic cause of stroke in the young. Neurol India 2018;66:232-4.  Back to cited text no. 21
[PUBMED]  [Full text]  
22.
Bersano A, Ballabio E, Bresolin N, Candelise L. Genetic polymorphisms for the study of multifactorial stroke. Hum Mutat 2008;29:776-95.  Back to cited text no. 22
    
23.
Stankovic S, Majkic-Singh N. Genetic aspects of ischemic stroke: Coagulation, homocysteine, and lipoprotein metabolism as potential risk factors. Crit Rev Clin Lab Sci 2010;47:72-123.  Back to cited text no. 23
    
24.
Calabrò RS, La Spina P, Serra S, Laganà A, Postorino P, Savica R, et al. Prevalence of prothrombotic polymorphisms in a selected cohort of cryptogenic and noncryptogenic ischemic stroke patients. Neurol India 2009;57:636-7.  Back to cited text no. 24
    
25.
Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: Thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004;61:1652-61.  Back to cited text no. 25
    
26.
Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: Evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-32.  Back to cited text no. 26
    
27.
Matarin M, Singleton A, Hardy J, Meschia J. The genetics of ischaemic stroke. J Intern Med 2010;267:139-55.  Back to cited text no. 27
    
28.
De Stefano V, Leone G. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica 1995;80:344-56.  Back to cited text no. 28
    
29.
Segers O, Simioni P, Tormene D, Bulato C, Gavasso S, Rosing J, et al. Genetic modulation of the FV (Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. J Thromb Haemost 2012;10:73-80.  Back to cited text no. 29
    
30.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.  Back to cited text no. 30
    
31.
Wouters MG, Boers GH, Blom HJ, Trijbels FJ, Thomas CM, Borm GF, et al. Hyperhomocysteinemia: A risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993;60:820-5.  Back to cited text no. 31
    
32.
Komanasin N, Catto AJ, Futers TS, van Hylckama Vlieg A, Rosendaal FR, Ariëns RA. A novel polymorphism in the factor XIII B-subunit (His95Arg): Relationship to subunit dissociation and venous thrombosis. J Thromb Haemost 2005;3:2487-96.  Back to cited text no. 32
    
33.
Ding Q, Yang L, Hassanian SM, Rezaie AR. Expression and functional characterisation of natural R147W and K150del variants of protein C in the Chinese population. Thromb Haemost 2013;109:614-24.  Back to cited text no. 33
    
34.
Morange PE, Oudot-Mellakh T, Cohen W, Germain M, Saut N, Antoni G, et al. KNG1 Ile581Thr and susceptibility to venous thrombosis. Blood 2011;117:3692-4.  Back to cited text no. 34
    
35.
Uitte de Willige S, Rietveld IM, De Visser MC, Vos HL, Bertina RM. Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio. J Thromb Haemost 2007;5:1243-9.  Back to cited text no. 35
    
36.
Antón AI, Teruel R, Corral J, Miñano A, Martínez-Martínez I, Ordóñez A, et al. Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. Haematologica 2009;94:589-92.  Back to cited text no. 36
    
37.
Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, et al. Gene variants associated with deep vein thrombosis. JAMA 2008;299:1306-14.  Back to cited text no. 37
    
38.
Snoep JD, Gaussem P, Eikenboom JC, Emmerich J, Zwaginga JJ, Holmes CE, et al. The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: Results from the SMILE-Platelets project. J Thromb Haemost 2010;8:2377-84.  Back to cited text no. 38
    
39.
Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998;91:2010-4.  Back to cited text no. 39
    
40.
Lichy C, Kropp S, Dong-Si T, Genius J, Dolan T, Hampe T, et al. A common polymorphism of the protein Z gene is associated with protein Z plasma levels and with risk of cerebral ischemia in the young. Stroke 2004;35:40-5.  Back to cited text no. 40
    
41.
Li Y, Bezemer ID, Rowland CM, Tong CH, Arellano AR, Catanese JJ, et al., Genetic variants associated with deep vein thrombosis: The F11 locus. J Thromb Haemost 2009;7:1802-8.  Back to cited text no. 41
    
42.
Khaleghparast A, Khaleghparast S, Khaleghparast H. Association between the A1298C Polymorphism of the methylenetetrahydrofolate reductase gene and recurrent spontaneous abortion. Iran J Neonatol 2014;5:7-11.  Back to cited text no. 42
    
43.
Kreutz RP, Bitar A, Owens J, Desta Z, Breall JA, von der Lohe E, et al. Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. J Thromb Thrombolysis 2014;38:380-7.  Back to cited text no. 43
    
44.
Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: A systematic review and clinical update. Stroke 2017;48:867-72.  Back to cited text no. 44
    
45.
Lane DA, Mollica LR. Haemostatic gene polymorphisms in venous and arterial thrombosis. Pathophysiol Haemost Thromb 2002;32:213-5.  Back to cited text no. 45
    
46.
Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J 2003;146:948-57.  Back to cited text no. 46
    
47.
Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006;367:651-8.  Back to cited text no. 47
    
48.
Panigrahi I, Chatterjee T, Biswas A, Behari M, Choudhry PV, Saxena R. Role of MTHFR C677T polymorphism in ischemic stroke. Neurol India 2006;54:48-52.  Back to cited text no. 48
[PUBMED]  [Full text]  
49.
Das S, Roy S, Kaul S, Jyothy A, Munshi A. MTHFR gene (C677t) polymorphism in Ischemic stroke, its subtypes and hemorrhagic stroke in a South Indian population. Acta Med Int 2015;2:28-33.  Back to cited text no. 49
  [Full text]  
50.
Cui T. MTHFR C677T mutation increased the risk of Ischemic Stroke, especially in large-artery atherosclerosis in adults: An updated meta-analysis from 38 researches. Int J Neurosci 2016;126:10-9.  Back to cited text no. 50
    
51.
Zhang Z, Yan Q, Guo J, Wang X, Yuan W, Wang L, et al. A plasma proteomics method reveals links between ischemic stroke and MTHFR C677T genotype. Sci Rep 2017;7:13390.  Back to cited text no. 51
    
52.
Houlihan LM, Davies G, Tenesa A, Harris SE, Luciano M, Gow AJ, et al. Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. Am J Hum Genet 2010;86:626-31.  Back to cited text no. 52
    
53.
Hu Z, Liu J, Song Z, Hou Q, Fan X, Hou D. Variants in the atherogenic ALOX5AP, THBD, and KNG1 genes potentiate the risk of ischemic stroke via a genetic main effect and epistatic interactions in a Chinese population. J Stroke Cerebrovasc Dis 2015;24:2060-8.  Back to cited text no. 53
    
54.
Sabater-Lleal M, Martinez-Perez A, Buil A, Folkersen L, Souto JC, Bruzelius M, et al. A genome-wide association study identifies KNG1 as a genetic determinant of plasma factor XI Level and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2012;32:2008-16.  Back to cited text no. 54
    
55.
Hossmann V, Heiss WD, Bewermeyer H. Antithrombin III deficiency in ischaemic stroke. Klin Wochenschr 1983;61:617-20.  Back to cited text no. 55
    
56.
Nagaraja D, Christopher R, Tripathi M. Plasma antithrombin III deficiency in ischaemic stroke in the young. Neurol India 1999;47:155-6.  Back to cited text no. 56
[PUBMED]  [Full text]  
57.
Soria JM, Almasy L, Souto JC, Bacq D, Buil A, Faure A, et al. A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. Am J Hum Genet 2002;70:567-74.  Back to cited text no. 57
    
58.
Bach J, Endler G, Winkelmann BR, Boehm BO, Maerz W, Mannhalter C, et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008;6:291-6.  Back to cited text no. 58
    
59.
Kanaji T. Lower factor XII activity is a risk marker rather than a risk factor for cardiovascular disease: A rebuttal. J Thromb Haemost 2008;6:1053-6.  Back to cited text no. 59
    
60.
Tirado I, Soria JM, Mateo J, Oliver A, Souto JC, Santamaria A, et al. Association after linkage analysis indicates that homozygosity for the 46C-->T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004;91:899-904.  Back to cited text no. 60
    
61.
Santamaría A, Martínez-Rubio A, Mateo J, Tirado I, Soria JM, Fontcuberta J. Homozygosity of the T allele of the 46C-->T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. Haematologica 2004;89:878-9.  Back to cited text no. 61
    
62.
Santamaría A, Mateo J, Tirado I, Oliver A, Belvís R, Martí-Fábregas J, et al. Homozygosity of the T allele of the 46C->T polymorphism in the F12 gene is a risk factor for ischemic stroke in the Spanish population. Stroke 2004;35:1795-9.  Back to cited text no. 62
    
63.
Kanaji T, Watanabe K, Hattori S, Urata M, Iida H, Kinoshita S, et al. Factor XII gene (F12) -4C/C polymorphism in combination with low protein S activity is associated with deep vein thrombosis. Thromb Haemost 2006;96:854-5.  Back to cited text no. 63
    
64.
Undas A, Slowik A, Gissel M, Mann KG, Butenas S. Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events. Eur J Clin Invest 2012;42:123-9.  Back to cited text no. 64
    
65.
Li A, Jiao X, Munier FL, Schorderet DF, Yao W, Iwata F, et al. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am J Hum Genet 2004;74:817-26.  Back to cited text no. 65
    
66.
Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K, et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 2007;297:489-98.  Back to cited text no. 66
    
67.
Kapranov P, Willingham AT, Gingeras TR. Genome-wide transcription and the implications for genomic organization. Nat Rev Genet 2007;8:413-23.  Back to cited text no. 67
    



 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow